+7.03% for Injective as caution emerges on overbought signals
Injective (INJ) is trading at $5.47, marking a 7.03% gain on the day and maintaining a position above its key moving averages.
5.51
5.84
Highlights
- INJ/USD maintains a strong bullish trend, trading well above key moving averages and long-term support levels.
- Momentum indicators are overbought, but buyer dominance persists, driving the price toward the upper end of the daily range.
- Expected 1-day price range is $5.26 to $5.68, with high probability of further upside unless support at $5.21 fails.
Bullish momentum strengthened as technicals show overbought conditions
INJ/USD continues to hold above the MA-20 ($5.17) and MA-50 ($5.18) on the hourly chart. Daily support is strengthened by the MA-200 at $4.20, and the Ichimoku Kijun sits at $5.21 as the nearest support level. Momentum readings are robust, with MACD registered on Buy, while ADX signals Neutral conditions. Both the RSI (71.14), Stoch RSI, and CCI point to overbought territory. Intraday momentum is confirmed by BBP on Buy and the Awesome Oscillator, reflecting dominance by buyers amid ongoing volatility.
Upside remains likely as overbought risk tempers bullish view
In the short term, INJ is expected to trade within a $5.26 to $5.68 range, reflecting recent volatility and underlying bullish momentum. The probability of continued upward movement is very high, though short-term caution is warranted due to the presence of overbought signals across several oscillators. If consolidation occurs, the price is likely to remain within the current corridor, with upside potential if resistance is breached, and a downside scenario activated only if the asset loses support at $5.21.
Earlier, analysts noted that Injective was exhibiting mixed technical signals, resulting in a largely indecisive outlook. The latest surge in buying momentum and alignment above major moving averages now signals a renewed bullish bias, making the $5.68 level crucial for any potential breakout in the coming sessions.
Latest Injective News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
